Featured Post

Latest Gold News

Fed doves supporting gold Stronger rand crushing South African miners Economic power could shift further East with Hong Kong gold exch...

Wednesday, November 23, 2011

Pharmasset (VRUS) Downgraded by Analysts

Pharmasset (NASDAQ: VRUS) was downgraded by numerous analysts.

Pharmasset (VRUS) was downgraded by Noble Financial to a “Sell” rating.

Pharmasset was downgraded by William Blair to a “Market Perform” rating.

Pharmasset was downgraded by Brean Murray from a “Buy” rating to a “Hold” rating.

Pharmasset was downgraded by Wells Fargo & Co. (NYSE:WFC) from an “Outperform” rating to a “Market Perform” rating.

Pharmasset was downgraded by JPMorgan Chase & Co. (NYSE:JPMN) from an “Overweight” rating to a “Neutral” rating. They have a price target of $137.00 on the company.

Pharmasset was downgraded by Canaccord Genuity from a “Buy” rating to a “Hold” rating.

Pharmasset was downgraded by Leerink from an “Outperform” rating to a “Market Perform” rating.

Pharmasset was downgraded by UBS AG (NYSE:UBS) from a “Buy” rating to a “Neutral” rating.

No comments: